Liu Yan, Bo Zhenyan, Liu Dan, Diao Sha, Yang Chunsong, Li Hailong, Zeng Linan, Yu Qin, Zhang Lingli
Department of Pharmacy, West China Second University Hospital, Sichuan University, Chengdu, China.
Evidence-Based Pharmacy Center, West China Second University Hospital, Sichuan University, Chengdu, China.
Ann Transl Med. 2022 Mar;10(6):327. doi: 10.21037/atm-22-1050.
Research on pharmacoeconomics (PE) promotes the rational allocation of medical resources, which has received attention in the last decade. We conducted a scientometric analysis of PE to determine the current status and frontiers, and promote cooperation and development.
The Web of Science Core Collection-Science Citation Index Expanded was adopted to retrieve publications associated with PE from 2012-2021. After screening publications, CiteSpace 3.8.R3 was used to conduct a scientometric analysis. We analyzed terms, including publications and citations, countries/regions, institutions, journals, authors, keywords, and references.
In total, 4,715 documents published from 2012-2021 were included in this study, of which 3,829 were articles and 886 were reviews. The documents were cited 54,596 times, at an average of 11.58 times per document. 121 countries/regions and 410 institutions were involved. The top 3 countries/regions by the number of publications were the United States of America (n=1,790), England (n=601), and China (n=403), while the institution with the most publications was Pfizer. was the main journal of PE, with 310 publications in all, and the top 3 cited journals were (citation times =1,620), (citation times =1,306), and (citation times =1,255). Bin Wu was the most productive author (n=16), while World Health Organization was the most influential author (citation times =387). 524 keywords altogether were found, and the top 3 keywords by frequency were therapy (frequency =318), impact (frequency =305), and cost-effectiveness (frequency =296). The keyword "modifying antirheumatic drug" associated with rheumatoid arthritis (RA) has continued bursting from 2016-2021. by the National Institute for Health and Care Excellence, was the most frequently cited publication on PE (citation times =65). Cluster 0 labeled as "cost-effectiveness analysis" (CEA) was the largest and latest cluster, and its citing articles focused on the CEA of first-line treatment for non-small cell lung cancer (NSCLC).
The economic analysis of disease-modifying antirheumatic drugs related to RA was a popular topic in the last 6 years, and CEA of NSCLC first-line treatment was at the frontier of PE.
药物经济学（PE）研究促进了医疗资源的合理配置，在过去十年中受到了关注。我们对药物经济学进行了科学计量分析，以确定其现状和前沿领域，并促进合作与发展。
采用科学引文索引扩展版（Web of Science核心合集）检索2012年至2021年与药物经济学相关的出版物。在筛选出版物后，使用CiteSpace 3.8.R3进行科学计量分析。我们分析了包括出版物和引文、国家/地区、机构、期刊、作者、关键词和参考文献等在内的术语。
本研究共纳入2012年至2021年发表的4715篇文献，其中3829篇为文章，886篇为综述。这些文献被引用54596次，平均每篇文献被引用11.58次。涉及121个国家/地区和410个机构。按出版物数量排名前3的国家/地区是美国（n = 1790）、英国（n = 601）和中国（n = 403），而发表文献最多的机构是辉瑞公司。《药物经济学》是药物经济学的主要期刊，共发表了310篇文献，被引用次数排名前3的期刊是《药物经济学》（引用次数 = 1620）、《临床治疗学》（引用次数 = 1306）和《价值健康》（引用次数 = 1255）。吴斌是发文量最多的作者（n = 16），而世界卫生组织是最具影响力的作者（引用次数 = 387）。共发现524个关键词，出现频率排名前3的关键词是治疗（频率 = 318）、影响（频率 = 305）和成本效益（频率 = 296）。与类风湿关节炎（RA）相关的关键词“改善病情抗风湿药”在2016年至2021年期间持续涌现。英国国家卫生与临床优化研究所发布的《药物经济学评价方法》是药物经济学领域被引用次数最多的出版物（引用次数 = 65）。标记为“成本效益分析”（CEA）的聚类0是最大且最新的聚类，其引用文章主要关注非小细胞肺癌（NSCLC）一线治疗的成本效益分析。
过去6年中，与类风湿关节炎相关的改善病情抗风湿药的经济学分析是一个热门话题，非小细胞肺癌一线治疗的成本效益分析处于药物经济学的前沿领域。
